Literature DB >> 7678304

Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.

M Ohlin1, V A Sundqvist, M Mach, B Wahren, C A Borrebaeck.   

Abstract

The humoral immune response to human cytomegalovirus (CMV) membrane glycoprotein gp58/116 (gB) has been studied by establishing cell lines producing specific human monoclonal antibodies. These cell lines were generated from peripheral blood lymphocytes obtained from a healthy carrier. Hybridomas producing gp58/116-specific antibodies were detected by reactivity to procaryotically expressed proteins containing the major neutralizing epitopes of this glycoprotein complex. One antibody, ITC88, which recognized an epitope located between amino acid residues 67 and 86 of gp116, potently neutralized the virus at 1 to 2 micrograms of immunoglobulin G per ml. Only four of the six human antibodies detecting the major neutralizing domain of gp58 neutralized the virus, and none of them required complement for activity. All antibodies that bound mature, processed gp58 recognized a conformational epitope involving sequences between residues 549 and 635. However, small differences existed between the antibodies in the actual minimal requirement for C- and N-terminal parts of this epitope. By peptide mapping with several of the antibodies, the epitope was shown to consist mainly of residues between amino acids 570 to 579 and 606 to 619. Despite the conformational nature of the epitope, the antibodies recognized both reduced and denatured native antigen. Presence of carbohydrates was not required for antigen binding of these gp58-specific human antibodies, but in at least one case, it greatly enhanced antigen recognition, indicating an importance of carbohydrate structures in some epitopes within the major neutralizing specificity of gp58.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678304      PMCID: PMC237421     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Antiviral activities of a human monoclonal antibody against human cytomegalovirus.

Authors:  T Tomiyama; Y Masuho
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

2.  Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes.

Authors:  S W Chou; K M Dennison
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  Lymphocyte and IgG responses to different herpes simplex virus antigens in patients with frequent HSV-1 reactivations.

Authors:  P Ljungman; L Zetterqvist; V A Sundqvist; S Jeansson; A Heimdahl; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

4.  Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage.

Authors:  R R Spaete; R M Thayer; W S Probert; F R Masiarz; S H Chamberlain; L Rasmussen; T C Merigan; C Pachl
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

5.  Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II.

Authors:  B Kari; R Gehrz
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Biochemical and immunological analysis of discontinuous epitopes in the family of human cytomegalovirus glycoprotein complexes designated gC-I.

Authors:  B Kari; R Gehrz
Journal:  J Gen Virol       Date:  1991-08       Impact factor: 3.891

7.  Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

Authors:  M Ohlin; V A Sundqvist; G Gilljam; U Rudén; F O Gombert; B Wahren; C A Borrebaeck
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

8.  Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus.

Authors:  J Darlington; M Super; K Patel; J E Grundy; P D Griffiths; V C Emery
Journal:  J Gen Virol       Date:  1991-08       Impact factor: 3.891

9.  IgG antibodies to human herpesvirus-6 in children and adults and in primary Epstein-Barr virus infections and cytomegalovirus infections [corrected].

Authors:  A Linde; H Dahl; B Wahren; E Fridell; Z Salahuddin; P Biberfeld
Journal:  J Virol Methods       Date:  1988-09       Impact factor: 2.014

10.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more
  42 in total

1.  Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.

Authors:  Peter Ellmark; Camilla Ottosson; Carl A K Borrebaeck; Ann-Christin Malmborg Hager; Christina Furebring
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

2.  Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions.

Authors:  Florent C Bender; Minu Samanta; Ekaterina E Heldwein; Manuel Ponce de Leon; Elina Bilman; Huan Lou; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

3.  Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Authors:  Christy A Thomson; Steve Bryson; Gary R McLean; A Louise Creagh; Emil F Pai; John W Schrader
Journal:  EMBO J       Date:  2008-09-04       Impact factor: 11.598

4.  Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

Authors:  M Ohlin; M Silvestri; V A Sundqvist; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

5.  Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

Authors:  Krista M McCutcheon; Julia Gray; Natalie Y Chen; Keyi Liu; Minha Park; Stote Ellsworth; Ralph A Tripp; S Mark Tompkins; Scott K Johnson; Shelly Samet; Lenore Pereira; Lawrence M Kauvar
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

6.  Identification and characterization of immunoglobulin G in blood as a major inhibitor of diagnostic PCR.

Authors:  W A Al-Soud; L J Jönsson; P Râdström
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 7.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

8.  Retrieval of human cytomegalovirus glycoprotein B from the infected cell surface for virus envelopment.

Authors:  K Radsak; M Eickmann; T Mockenhaupt; E Bogner; H Kern; A Eis-Hübinger; M Reschke
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Glycoprotein B switches conformation during murid herpesvirus 4 entry.

Authors:  Laurent Gillet; Susanna Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2008-06       Impact factor: 3.891

10.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.